An inflammatory marker needs a clinical question
The main question concerned mortality in sepsis, not a general immunity score.
TESTS: read the trial with its correction.
The main question concerned mortality in sepsis, not a general immunity score.
The comparison
TESTS compared thymosin α1 with placebo in adults with sepsis in China. It did not provide conclusive evidence of reduced 28-day mortality. Funders included public/university programs and SciClone Pharmaceuticals. The clinical population must remain visible when communicating the finding.
Use the corrected result
The May 2025 correction updated the primary-outcome hazard ratio to 0.97, with a 95% confidence interval of 0.76–1.24. It includes values compatible with different effect sizes and directions; it does not establish equivalence. Changes to immune data are also described in that correction.
Professional context / Contexto profesional
Assess design, analyses and possible subgroups with the protocol and supplements; do not claim universal safety.
Evidence / Evidencia
Phase 3 trial with a subsequent correction.
Limitations / Limitaciones
Does not test prevention in healthy people or justify self-medication.